Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 1
2007 1
2009 2
2010 2
2011 1
2012 3
2013 3
2014 6
2015 3
2016 5
2017 2
2018 1
2019 5
2020 9
2021 9
2022 9
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean pilar roles (312 results)?
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: eroles p. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: eroles p. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: eroles p. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Garrido-Cano I, et al. Among authors: eroles p. Cancer Metastasis Rev. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. Epub 2021 Sep 15. Cancer Metastasis Rev. 2022. PMID: 34524579 Free PMC article. Review.
Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Belltall A, Mazzinari G, Diaz-Cambronero O, Eroles P, Argente Navarro MP. Belltall A, et al. Among authors: eroles p. Curr Oncol Rep. 2022 Oct;24(10):1337-1349. doi: 10.1007/s11912-022-01295-z. Epub 2022 Jun 1. Curr Oncol Rep. 2022. PMID: 35648340 Free PMC article. Review.
MicroRNAs in Breast Cancer: One More Turn in Regulation.
Eroles P, Tormo E, Pineda B, Espin E, Lluch A. Eroles P, et al. Curr Drug Targets. 2016;17(9):1083-100. doi: 10.2174/1389450116666150213114103. Curr Drug Targets. 2016. PMID: 25694121 Review.
Emerging EGFR antagonists for breast cancer.
Lluch A, Eroles P, Perez-Fidalgo JA. Lluch A, et al. Among authors: eroles p. Expert Opin Emerg Drugs. 2014 Jun;19(2):165-81. doi: 10.1517/14728214.2014.903919. Epub 2014 May 15. Expert Opin Emerg Drugs. 2014. PMID: 24831079 Review.
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall D, Hernández-Prat A, García-Alonso S, Arpí-Llucià O, Menéndez S, Qin M, Guardia C, Morancho B, Sánchez-Martín FJ, Zazo S, Gavilán E, Sabbaghi MA, Eroles P, Cejalvo JM, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Casadevall D, et al. Among authors: eroles p. Mol Cancer Res. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. Mol Cancer Res. 2022. PMID: 35348729
66 results